Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC)
- Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV), including in patients with advanced disease
- Treatment with LIVMARLI® (maralixibat) demonstrates improved event-free survival in patients with progressive familial intrahepatic cholestasis (PFIC)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b VISTAS study of volixibat in PSC and Phase 2b AZURE-1 study of brelovitug in HDV, alongside data featuring its established therapy, LIVMARLI® (maralixibat), in PFIC, were presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2026.
